Study validates effectiveness of genomic test for lung cancer detection

May 17, 2015

(Boston) -- A new test co-developed by a Boston University School of Medicine (BUSM) researcher will allow patients suspected of having lung cancer to be subjected to fewer and less-invasive tests to determine if they have the disease.

"We are seeing an increase in the number of lesions suspicious for lung cancer found on chest imaging of current and former smokers. In the past, these patients have been subjected to invasive tests when traditional bronchoscopy tests prove inconclusive. Today's announcement provides physicians and patients with an additional piece of scientifically reliable information to consider when determining their next diagnostic step," said senior author Avi Spira, MD, MSc, professor of medicine, pathology and bioinformatics at BUSM.

Researchers have found that a genomic biomarker can accurately determine the likelihood of a lung lesion being malignant. The findings that appear online in the New England Journal of Medicine are from two large, prospective, multicenter studies called Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer (AEGIS) I and II. These findings will allow physicians to confidently identify patients who are at low probability for having lung cancer thus sparing them from costly and risky procedures.

The Impact

"While the test itself is simple, the science behind it is remarkable," added Spira who also is the Alexander Graham Bell Professor in Health Care Entrepreneurship at BUSM. Previous work by Spira found that the pattern of gene activity in cells lining the upper respiratory tract can identify cancer that is developing deeper in the lung. "The ability to test for molecular changes in this 'field of injury' allows us to rule out the disease earlier without invasive procedures. Conceptually, this may have significant implications for other diseases."

Study Details

The study involved 639 patients (298 in AEGIS I and 341 in AEGIS II) at 28 sites in the United States, Canada and Ireland who were undergoing bronchoscopy, a common nonsurgical procedure to assess lung lesions for cancer. Using airways cells collected by the bronchoscopy, the researchers found this genomic test, when evaluated with the bronchoscopy, had a combined sensitivity of 97 percent for detecting lung cancer, compared to 75 percent for bronchoscopy alone.

"This study validates the effectiveness of the bronchial genomic biomarker among those undergoing bronchoscopy in two independent groups. We found that it has high sensitivity across different sizes, locations, stages and cell types of lung cancer," added Spira. "The combination of the biomarker and bronchoscopy has a sensitivity of 96 percent and 98 percent in the AEGIS-1 and AEGIS-2 groups, respectively."

An estimated 250,000 patients undergo a bronchoscopy for suspected lung cancer each year with approximately 40 percent producing non-diagnostic results. This can lead to invasive procedures such as transthoracic needle biopsy or surgical lung biopsy that are risky and expensive. "In intermediate risk patients with a non-diagnostic bronchoscopy, a negative genomic test warrants consideration of a more conservative diagnostic approach that could reduce unnecessary invasive testing in patients without lung cancer. We hope to improve the diagnostic work up for lung cancer by reducing patient anxiety, performing fewer unnecessary procedures and ultimately saving valuable healthcare resources and money," Spira said.
-end-
This study was co- led by Gerard Silvestri, MD, MS, from the Medical University of South Carolina and Anil Vachani, MD, MS, from the University of Pennsylvania School of Medicine.

Funding for this study was provided by Allegro Diagnostics Corp., NIH 1R44CA139803, and NIH/NCI U01 CA152751 as part of the Early Detection Research Network (EDRN).

DISCLOSURE:

Dr. Spira reports personal fees from Allegro Diagnostics, Inc., personal fees from Veracyte, Inc., grants from NIH/NCI EDRN U01 CA152751, grants from DOD DECAMP W81XWH-11-2-0161, during the conduct of the study; personal fees from Allegro Diagnostics, Inc., personal fees from Veracyte, Inc., outside the submitted work. In addition, Dr. Spira has a patent 11/918,558: Diagnostic for lung disorders using class prediction licensed to Allegro Diagnostics, Inc., a patent 12/414,555: Multifactorial methods for detecting lung disorders licensed to Allegro Diagnostics, Inc., and a patent Detection methods for disorders of the lung licensed to Allegro Diagnostics, Inc.

Boston University Medical Center

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.